{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:39:26Z","timestamp":1790401166333,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["3333"],"award-info":[{"award-number":["3333"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the low prevalence of uveitis in pediatric rheumatic diseases, potential problems as well as high disease burden can complicate its management. In this review, we systematically assessed the epidemiological, etiological, and managerial aspects of uveitis in pediatric rheumatic diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This current study was conducted in accordance with the established methods and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). We searched the manuscript databases, including Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane for all eligible studies in line with the considered keywords. We also conducted the statistical analysis using the Stata software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Considering studies focusing on uveitis in Juvenile Idiopathic Arthritis (JIA) yielded a pooled prevalence of 11.8% (95%CI: 11.2 to 12.4%) for uveitis following JIA. In this regard, the prevalence rate of uveitis related to Beh\u00e7et<jats:sup>,<\/jats:sup>s disease and Systemic Lupus Erythematosus (SLE( was estimated to be 15.0 and 0.8%, respectively. The pooled response rate to Adalimumab and Infliximab was estimated to be 68.0% (95%CI: 65.4 to 70.6%), 64.7% (95%CI: 59.8 to 69.3%), respectively. The documents for the systematical assessment of other biological medications (e.g. Tocilizumab, Daclizumab and Rituximab) were inadequate; however, the mean response rate for these drugs was 59, 75 and 80%, respectively. Our meta-analysis showed a pooled response rate of 40.0% (95%CI, 36.0% to 44.2) to Methotrexate. Significant heterogeneity and significant diffusion bias were demonstrated by reviewing studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The pooled prevalence of uveitis in pediatric rheumatic diseases widely varied based on the underlying disease requiring more investigations in different subtypes of rheumatic diseases. The biologic medications, especially Adalimumab are the most effective treatments for uveitis in pediatric rheumatic diseases; however, a combination of the safe, available alternatives is preferred to achieve the most desirable treatment response.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-020-1324-x","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T13:02:39Z","timestamp":1580821359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-6794","authenticated-orcid":false,"given":"Mohsen","family":"Jari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Salehpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khosro","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"4","key":"1324_CR1","first-page":"365","volume":"24","author":"ET Cunningham Jr","year":"2016","unstructured":"Cunningham ET Jr, Smith JR, Tugal-Tutkun I, Rothova A, Zierhut M. Uveitis in Children and Adolescents. OculImmunol Inflamm. 2016;24(4):365\u201371.","journal-title":"OculImmunol Inflamm"},{"issue":"3","key":"1324_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/0974-620X.122267","volume":"6","author":"PD Majumder","year":"2013","unstructured":"Majumder PD, Biswas J. Pediatric uveitis: An update. Oman J Ophthalmol. 2013;6(3):140\u201350.","journal-title":"Oman J Ophthalmol"},{"issue":"1","key":"1324_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40674-017-0057-z","volume":"3","author":"AB Sood","year":"2017","unstructured":"Sood AB, Angeles-Han ST. An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis. CurrTreatm Opt Rheumatol. 2017;3(1):1\u201316.","journal-title":"CurrTreatm Opt Rheumatol"},{"issue":"4","key":"1324_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/00148581-200911040-00002","volume":"11","author":"SM Sharma","year":"2009","unstructured":"Sharma SM, Dick AD, Ramanan AV. Non-infectious pediatric uveitis: an update on immunomodulatory management. Paediatr Drugs. 2009;11(4):229\u201341.","journal-title":"Paediatr Drugs"},{"issue":"jan02 1","key":"1324_CR5","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(jan02 1):g7647.","journal-title":"BMJ"},{"issue":"1","key":"1324_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2\u201310.","journal-title":"J Evid Based Med"},{"issue":"1","key":"1324_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12969-017-0195-8","volume":"15","author":"E Nordal","year":"2017","unstructured":"Nordal E, Rypdal V, Christoffersen T, Aalto K, Berntson L, Fasth A, Herlin T, Nielsen S, Peltoniemi S, Straume B, Zak M, Rygg M, Nordic Study Group of Pediatric Rheumatology (NoSPeR). Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study. Pediatr Rheumatol Online J. 2017;15(1):66.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpeds.2017.03.052","volume":"186","author":"E Sardar","year":"2017","unstructured":"Sardar E, Dusser P, Rousseau A, Bodaghi B, Labetoulle M, Kon\u00e9-Paut I. Retrospective Study Evaluating Treatment Decisions and Outcomes of Childhood Uveitis Not Associated with Juvenile Idiopathic Arthritis. J Pediatr. 2017;186:131\u2013137.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.03.052 Epub 2017 Apr 27.","journal-title":"J Pediatr"},{"issue":"3","key":"1324_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10067-016-3534-0","volume":"36","author":"PP Kahwage","year":"2017","unstructured":"Kahwage PP, Ferriani MP, Furtado JM, de Carvalho LM, Pileggi GS, Gomes FH, Terreri MT, Magalh\u00e3es CS, Pereira RM, Sacchetti SB, Marini R, Bonf\u00e1 E, Silva CA, Ferriani VP. Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. ClinRheumatol. 2017;36(3):547\u201353. https:\/\/doi.org\/10.1007\/s10067-016-3534-0 Epub 2017 Jan 9.","journal-title":"ClinRheumatol"},{"issue":"4","key":"1324_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/jpc.13450","volume":"53","author":"V Cecchin","year":"2017","unstructured":"Cecchin V, Sperotto F, Balzarin M, Vittadello F, Martini G, Zulian F. Joint hypermobility and oligoarticular juvenile idiopathic arthritis: What relationship? Paediatr Child Health. 2017;53(4):374\u20137. https:\/\/doi.org\/10.1111\/jpc.13450 Epub 2017 Jan 4.","journal-title":"Paediatr Child Health"},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","volume":"13","author":"ST Angeles-Han","year":"2015","unstructured":"Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, Vogler LB, Lambert SR, Drews-Botsch C, Prahalad S. Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis. Pediatr Rheumatol Online J. 2015;13:19. https:\/\/doi.org\/10.1186\/s12969-015-0018-8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"1324_CR12","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3899\/jrheum.130302","volume":"40","author":"ST Angeles-Han","year":"2013","unstructured":"Angeles-Han ST, Pelajo CF, Vogler LB, Rouster-Stevens K, Kennedy C, Ponder L, McCracken C, Lopez-Benitez J, Drews-Botsch C, Prahalad S, CARRA Registry Investigators. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40(12):2088\u201396. https:\/\/doi.org\/10.3899\/jrheum.130302 Epub 2013 Nov 1.","journal-title":"J Rheumatol"},{"issue":"4","key":"1324_CR13","first-page":"633","volume":"31","author":"LA Clarke","year":"2013","unstructured":"Clarke LA, Guex-Crosier Y, Hofer M. Epidemiology of uveitis in children over a 10-year period. ClinExpRheumatol. 2013;31(4):633\u20137 Epub 2013 Feb 22.","journal-title":"ClinExpRheumatol"},{"issue":"4","key":"1324_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jmii.2012.03.006","volume":"46","author":"CC Shen","year":"2013","unstructured":"Shen CC, Yeh KW, Ou LS, Yao TC, Chen LC, Huang JL. Clinical features of children with juvenile idiopathic arthritis using the ILAR classification criteria: a community-based cohort study in Taiwan. JMicrobiolImmunol Infect. 2013;46(4):288\u201394. https:\/\/doi.org\/10.1016\/j.jmii.2012.03.006 Epub 2012 Jun 21.","journal-title":"JMicrobiolImmunol Infect"},{"issue":"2","key":"1324_CR15","first-page":"367","volume":"26","author":"JK Reininga","year":"2008","unstructured":"Reininga JK, Los LI, Wulffraat NM, Armbrust W. The evaluation of uveitis in juvenile idiopathic arthritis (JIA) patients: are current ophthalmologic screening guidelines adequate? ClinExpRheumatol. 2008;26(2):367\u201372.","journal-title":"ClinExpRheumatol"},{"issue":"5","key":"1324_CR16","first-page":"1139","volume":"34","author":"A Grassi","year":"2007","unstructured":"Grassi A, Corona F, Casellato A, Carnelli V, Bardare M. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. JRheumatol. 2007;34(5):1139\u201345 Epub 2007 Mar 1.","journal-title":"JRheumatol"},{"issue":"12","key":"1324_CR17","first-page":"993","volume":"222","author":"A Heiligenhaus","year":"2005","unstructured":"Heiligenhaus A, Niewerth M, Mingels A, Ganser G, Thon A, Pleyer U, Greiner K, Minden K. Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and ophthalmologic database. KlinMonblAugenheilkd. 2005;222(12):993\u20131001.","journal-title":"KlinMonblAugenheilkd"},{"issue":"10","key":"1324_CR18","first-page":"2031","volume":"24","author":"EC Chalom","year":"1997","unstructured":"Chalom EC, Goldsmith DP, Koehler MA, Bittar B, Rose CD, Ostrov BE, Keenan GF. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. JRheumatol. 1997;24(10):2031\u20134.","journal-title":"JRheumatol"},{"issue":"2","key":"1324_CR19","first-page":"101","volume":"34","author":"L Akduman","year":"1997","unstructured":"Akduman L, Kaplan HJ, Tychsen L. Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis.JPediatrOphthalmol. Strabismus. 1997;34(2):101\u20136.","journal-title":"Strabismus"},{"issue":"2","key":"1324_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","volume":"37","author":"CK Correll","year":"2017","unstructured":"Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. ClinRheumatol. 2017;37(2):549. https:\/\/doi.org\/10.1007\/s10067-017-3890-4 [Epub ahead of print].","journal-title":"ClinRheumatol"},{"issue":"1","key":"1324_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1324_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaapos.2015.12.006","volume":"20","author":"C Castiblanco","year":"2016","unstructured":"Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J AAPOS. 2016;20(2):145\u20137. https:\/\/doi.org\/10.1016\/j.jaapos.2015.12.006.","journal-title":"J AAPOS"},{"issue":"1","key":"1324_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12969-016-0069-5","volume":"14","author":"LA Henderson","year":"2016","unstructured":"Henderson LA, Zurakowski D, Angeles-Han ST, Lasky A, Rabinovich CE. Lo MS; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Investigators Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. PediatrRheumatol Online J. 2016;14(1):9. https:\/\/doi.org\/10.1186\/s12969-016-0069-5.","journal-title":"PediatrRheumatol Online J"},{"issue":"5","key":"1324_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","volume":"75","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K. Long-term safety of etanercept and adalimumabcompared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75(5):855\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-annrheumdis-2014-206747 Epub 2015 Apr 29.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1324_CR25","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. ArthritisRheumatol. 2014;66(9):2580\u20139. https:\/\/doi.org\/10.1002\/art.38741.","journal-title":"ArthritisRheumatol"},{"key":"1324_CR26","doi-asserted-by":"publisher","first-page":"560632","DOI":"10.1155\/2013\/560632","volume":"2013","author":"C Garc\u00eda-De-Vicu\u00f1a","year":"2013","unstructured":"Garc\u00eda-De-Vicu\u00f1a C, D\u00edaz-Llopis M, Salom D, Bou R, D\u00edaz-Cascajosa J, Cordero-Coma M, Ortega G, Ortego-Centeno N, Suarez-De-Figueroa M, Cruz-Mart\u00ednez J, Fonollosa A, Blanco R, Garc\u00eda-Aparicio \u00c1M, Ben\u00edtez-Del-Castillo JM, Ant\u00f3n J. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. MediatorsInflamm. 2013;2013:560632. https:\/\/doi.org\/10.1155\/2013\/560632 Epub 2013 Dec 30.","journal-title":"MediatorsInflamm"},{"issue":"8","key":"1324_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3899\/jrheum.121180","volume":"40","author":"MA Lerman","year":"2013","unstructured":"Lerman MA, Burnham JM, Chang PY, Daniel E, Foster CS, Hennessy S, Jabs DA, Joffe MM, Ka\u00e7maz RO, Levy-Clarke GA, Mills MD, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Kempen JH. Response of pediatric uveitis to tumor necrosis factor-\u03b1 inhibitors. J Rheumatol. 2013;40(8):1394\u2013403. https:\/\/doi.org\/10.3899\/jrheum.121180 Epub 2013 Jul 1.","journal-title":"J Rheumatol"},{"key":"1324_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1546-0096-11-16","volume":"11","author":"G Simonini","year":"2013","unstructured":"Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, Pagnini I, Lepore L, Cimaz R. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-\u03b1 therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16. https:\/\/doi.org\/10.1186\/1546-0096-11-16 eCollection 2013.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1324_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74\u20139. https:\/\/doi.org\/10.3899\/jrheum.120583 Epub 2012 Nov 1.","journal-title":"J Rheumatol"},{"issue":"2","key":"1324_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/03009742.2010.517546","volume":"40","author":"M Trachana","year":"2011","unstructured":"Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40(2):101\u20137. https:\/\/doi.org\/10.3109\/03009742.2010.517546 Epub 2010 Nov 25.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"1324_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynj\u00e4l\u00e4","year":"2008","unstructured":"Tynj\u00e4l\u00e4 P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/kem356 Epub 2008 Jan 31.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1324_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","volume":"91","author":"M Gallagher","year":"2007","unstructured":"Gallagher M, Quinones K, Cervantes-Casta\u00f1eda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341\u20134 Epub 2007 Jun 7.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1324_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"LB Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572\u20135.","journal-title":"J Pediatr"},{"issue":"3","key":"1324_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3899\/jrheum.160072","volume":"44","author":"FA Aeschlimann","year":"2017","unstructured":"Aeschlimann FA, Angst F, Hofer KD, Cannizzaro Schneider E, Schroeder-Kohler S, Lauener R, van der Kleij D, Rispens T, Saurenmann RK. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and\/or Uveitis: A Retrospective Longitudinal Cohort Study. J Rheumatol. 2017;44(3):334\u201341. https:\/\/doi.org\/10.3899\/jrheum.160072 Epub 2017 Jan 15.","journal-title":"J Rheumatol"},{"issue":"7","key":"1324_CR35","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3899\/jrheum.131231","volume":"41","author":"FA Aeschlimann","year":"2014","unstructured":"Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. Rheumatol. 2014;41(7):1409\u201315. https:\/\/doi.org\/10.3899\/jrheum.131231 Epub 2014 May 15.","journal-title":"Rheumatol"},{"issue":"10","key":"1324_CR36","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. JRheumatol. 2013;40(10):1749\u201355. https:\/\/doi.org\/10.3899\/jrheum.130133 Epub 2013 Aug 15.","journal-title":"JRheumatol"},{"issue":"6","key":"1324_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jaapos.2008.08.007","volume":"12","author":"I Tugal-Tutkun","year":"2008","unstructured":"Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitistreated with infliximab. J AAPOS. 2008;12(6):611\u20133. https:\/\/doi.org\/10.1016\/j.jaapos.2008.08.007 Epub 2008 Oct 19.","journal-title":"J AAPOS"},{"issue":"6","key":"1324_CR38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","volume":"144","author":"SP Ardoin","year":"2007","unstructured":"Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844\u20139 Epub 2007 Oct 22.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1324_CR39","first-page":"139","volume":"32","author":"SK de Oliveira","year":"2007","unstructured":"de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center. Acta Reumatol Port. 2007;32(2):139.","journal-title":"Acta Reumatol Port"},{"issue":"4","key":"1324_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P Tynj\u00e4l\u00e4","year":"2007","unstructured":"Tynj\u00e4l\u00e4 P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548\u201350 Epub 2006 Oct 26.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1324_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308\u201314 Epub 2006 Jan 10.","journal-title":"Ophthalmology"},{"issue":"1","key":"1324_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08820538.2013.839802","volume":"29","author":"MU Saeed","year":"2014","unstructured":"Saeed MU, Raza SH, Goyal S, Cleary G, Newman WD, Chandna A. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol. 2014;29(1):1\u20133. https:\/\/doi.org\/10.3109\/08820538.2013.839802 Epub 2013 Oct 31.","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"1324_CR43","first-page":"1146","volume":"34","author":"I Foeldvari","year":"2007","unstructured":"Foeldvari I, Nielsen S, K\u00fcmmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitisrefractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146\u201350 Epub 2007 Mar 1.","journal-title":"J Rheumatol"},{"issue":"2","key":"1324_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3899\/jrheum.160908","volume":"44","author":"E Quesada-Masachs","year":"2017","unstructured":"Quesada-Masachs E, Caballero CM. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis. J Rheumatol. 2017;44(2):260\u20131. https:\/\/doi.org\/10.3899\/jrheum.160908.","journal-title":"J Rheumatol"},{"issue":"12","key":"1324_CR45","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicu\u00f1a CG, Heiligenhaus A. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. JRheumatol. 2016;43(12):2183\u20138 Epub 2016 Sep 15.","journal-title":"JRheumatol."},{"issue":"6","key":"1324_CR46","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","volume":"100","author":"E Miserocchi","year":"2016","unstructured":"Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306790 Epub 2015 Sep 22.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1324_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jbspin.2008.10.015","volume":"76","author":"I Marvillet","year":"2009","unstructured":"Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76(4):383\u20138. https:\/\/doi.org\/10.1016\/j.jbspin.2008.10.015 Epub 2009 Jun 12.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"1324_CR48","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jpeds.2013.03.047","volume":"163","author":"C Papadopoulou","year":"2013","unstructured":"Papadopoulou C, Kostik M, B\u00f6hm M, Nieto-Gonzalez JC, Gonzalez-Fernandez MI, Pistorio A, Martini A, Ravelli A. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163(3):879\u201384. https:\/\/doi.org\/10.1016\/j.jpeds.2013.03.047 Epub 2013 May 9.","journal-title":"J Pediatr"},{"issue":"2","key":"1324_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","volume":"151","author":"V KalininaAyuso","year":"2011","unstructured":"KalininaAyuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217\u201322. https:\/\/doi.org\/10.1016\/j.ajo.2010.08.021 Epub 2010 Dec 9.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1324_CR50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/112067210701700509","volume":"17","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17(5):743\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"1324_CR51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3928\/0191-3913-19990501-09","volume":"36","author":"AK Shetty","year":"1999","unstructured":"Shetty AK, Zganjar BE, Ellis GS Jr, Ludwig IH, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoidiritis. J Pediatr Ophthalmol Strabismus. 1999;36(3):125\u20138.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"2","key":"1324_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0022-3476(98)70232-X","volume":"133","author":"AH Weiss","year":"1998","unstructured":"Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133(2):266\u20138.","journal-title":"J Pediatr"},{"issue":"1","key":"1324_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12969-017-0189-6","volume":"15","author":"ES Sen","year":"2017","unstructured":"Sen ES, Morgan MJ, MacLeod R, Strike H, Hinchcliffe A, Dick AD, Muthusamy B, Ramanan AV. Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2017;15(1):58.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1324_CR54","first-page":"52","volume":"71","author":"A Cosickic","year":"2017","unstructured":"Cosickic A, Halilbasic M, Selimovic A, Avdagic H. Uveitis Associated with Juvenile Idiopathic Arthritis, our Observations. Mediev Archaeol. 2017;71(1):52\u20135.","journal-title":"Mediev Archaeol"},{"issue":"6","key":"1324_CR55","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1167\/iovs.13-13444","volume":"55","author":"K Walscheid","year":"2014","unstructured":"Walscheid K, Hennig M, Heinz C, Wasmuth S, Busch M, Bauer D, Dietzel M, Deeg CA, Heiligenhaus A. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis. Invest Ophthalmol Vis Sci. 2014;55(6):3447\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1324_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/09273948.2013.871565","volume":"22","author":"I Tugal-Tutkun","year":"2014","unstructured":"Tugal-Tutkun I, Quartier P, Bodaghi B. Disease of the year: juvenile idiopathic arthritis-associated uveitis--classification and diagnostic approach. Ocul Immunol Inflamm. 2014;22(1):56\u201363.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1324-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1324-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T09:32:47Z","timestamp":1665739967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1324-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1324-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"26 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No patient data were included in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}